Antithrombotic Therapy in Patients with Recent Stroke and Atrial Fibrillation-Reference-Cited by-同舟云学术

Antithrombotic Therapy in Patients with Recent Stroke and Atrial Fibrillation

Published:2020-07-14 Issue:23 Volume:26 Page:2715-2724
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Saberwal Bunny¹^ORCID,Ioannou Adam²^ORCID,Lim Wei Y.¹,Beirne Anne-Marie¹^ORCID,Chow Anthony W.¹^ORCID,Tousoulis Dimitris³^ORCID,Ahsan Syed¹^ORCID,Papageorgiou Nikolaos¹^ORCID

Affiliation:

1. Electrophysiology Department, Barts Heart Centre, St. Bartholomew’s Hospital, London EC1A 7BE, United Kingdom

2. Royal Free Hospital, London NW3 2QG, United Kingdom

3. First Cardiology Department, Hippokration Hospital, Athens University Medical School, Athens, Greece

Abstract

: Atrial fibrillation (AF) is a common arrhythmia which carries a significant risk of stroke. Secondary prevention, particularly in the acute phase of stroke with anti-thrombotic therapy, has not been validated. The aim of this review is to evaluate the available evidence on the use of antithrombotic therapy in patients with recent stroke who have AF, and suggest a treatment algorithm for the various time points, taking into account both the bleeding and thrombosis risks posed at each stage.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference96 articles.

1. Lip G.Y.H.; Brechin C.M.; Lane D.A.; The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012,142(6),1489-1498

2. Chugh S.S.; Havmoeller R.; Narayanan K.; Singh D.; Rienstra M.; Benjamin E.J.; Gillum R.F.; Kim Y.H.; McAnulty J.H.; Zheng Z.J.; Forouzanfar M.H.; Naghavi M.; Mensah G.A.; Ezzati M.; Murray C.J.; Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014,129(8),837-847

3. Magnussen C.; Niiranen T.J.; Ojeda F.M.; Gianfagna F.; Blankenberg S.; Njølstad I.; Vartiainen E.; Sans S.; Pasterkamp G.; Hughes M.; Costanzo S.; Donati M.B.; Jousilahti P.; Linneberg A.; Palosaari T.; de Gaetano G.; Bobak M.; den Ruijter H.M.; Mathiesen E.; Jørgensen T.; Söderberg S.; Kuulasmaa K.; Zeller T.; Iacoviello L.; Salomaa V.; Schnabel R.B.; Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation BiomarCaRE Consortium2017,136(17),1588-1597

4. Allan V.; Honarbakhsh S.; Casas J.P.; Wallace J.; Hunter R.; Schilling R.; Perel P.; Morley K.; Banerjee A.; Hemingway H.; Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost 2017,117(5),837-850

5. Wakili R.; Voigt N.; Käb S.; Dobrev D.; Nattel S.; Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 2011,121(8),2955-2968

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Red Cell Distribution Width: A Routinely Available Biomarker with Important Clinical Implications in Patients with Atrial Fibrillation;Current Pharmaceutical Design;2021-10

2. Current Antithrombotic Therapy: Beyond Coronary Artery Disease;Current Pharmaceutical Design;2020-07-14